Video

Dr. Tannir on CANTATA study of telaglenastat plus cabozantinib in mRCC

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting: Bladder Cancer and RCC

Nizar M. Tannir, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.

Nizar M. Tannir, MD, MD Anderson Cancer Center, discusses results from the phase 2 CANTATA study of cabozantinib (Cabometyx) plus either the novel glutaminase inhibitor telaglenastat (CB-839) or placebo in patients with advanced/metastatic renal cell carcinoma who progressed on immune checkpoint inhibitors or antiangiogenic therapies.

Related Videos
Related Content
Expanded Access Program to provide real-world data on cretostimogene grenadenorepvec
December 11th 2024

Expanded Access Program to provide real-world data on cretostimogene grenadenorepvec

Hannah Clarke
Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy for patients with BCG-unresponsive high-risk NMIBC.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
December 9th 2024

High cystectomy-free survival seen with nadofaragene treatment in NMIBC

Benjamin P. Saylor
"Overall, the take-home message is that in patients with BCG-unresponsive non–muscle invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients," said Vikram Narayan, MD.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
December 6th 2024

Gemcitabine-BCG shows early promise in BCG-exposed NMIBC

Benjamin P. Saylor
CR rate was 98% (39/40) at 3 months, 94% at 6 months (34/36), and 81% at 12 months (21/26).
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
December 6th 2024

SunRISe-1 data point to safety, tolerability of TAR-200 in NMIBC

Benjamin P. Saylor
As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.
© 2024 MJH Life Sciences

All rights reserved.